AACE Response to Insulin Glargine Cancer Risk Articles in Diabetologia
JACKSONVILLE, Fla., June 29 /PRNewswire-USNewswire/ -- On June 26, 2009 several articles published online in Diabetologia by the European Association for the Study of Diabetes investigated the possible relationship between use of insulin glargine
(Lantus, sanofi-aventis) and the developm...
Statement from IDF on studies suggesting possible link between insulin glargine and cancer
The International Diabetes Federation (IDF) today called for urgent assessment and responses from regulatory authorities into a possible link between the use of insulin glargine
(an insulin analogue) and increased risk of cancer based on findings published on 26 June, 2009 in Diabetelogia , the j...
Expert Statement Issued about Lantus(R) Following Recent Publications in Diabetologia
...tions of registry analyses with Lantus(R) (insulin glargine
[rDNA] injection) in Diabetologia . This board of...results regarding a potential link between insulin glargine
use and an increased risk of cancer.
"R...nce do not indicate an association between insulin glargine
FDA Tells Patients to Stick With Diabetes Drug Linked to Cancer
... whether an association between the use of insulin glargine
and cancer truly exists."
The agency also beli...ion echoed the FDA's position. "For patients using glargine
and considering switching to another form of insul...nts to report side effects from the use of insulin glargine
to the FDA's MedWatch Adverse Event Reporting Prog...
Apidra(R) SoloSTAR(R), the Easy-to-Use Insulin Delivery Device from sanofi-aventis, Now Available in the United States
The availability of Apidra(R) SoloSTAR(R), approved in the U.S. in February 2009, follows the approval and launch of Lantus(R) SoloSTAR(R) (insulin glargine
[rDNA origin] injection) in 2007. People living with diabetes who use both Lantus(R) and Apidra(R) to help manage their blood sugar now have two pen d...
Long-acting insulin analogues in type 2 diabetes: advantage over human insulin not proven
...AIAs for the treatment of type 2 diabetes (insulin glargine
and insulin detemir) with human insulin, or compar...d various treatment schemes. This study on insulin glargine
lasted 5 years; all the other studies lasted a max...table that in 7 of the 9 studies comparing insulin glargine
and human insulin, the drugs were not used as norm...
Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R)
...ype 2 Diabetes
BRIDGEWATER, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced today its long-acting insulin Lantus(R) (insulin glargine
[rDNA origin] injection) and rapid-acting insulin Apidra(R) (insulin glulisine [rDNA origin] injection) will be the primary 2009 sponsors of Team Type...
Amylin Pharmaceuticals Reports 2008 Financial Results
...ent of DURATION-3, the third in a planned program of superiority clinical studies of exenatide once weekly, comparing exenatide once weekly to insulin glargine
in patients using oral diabetes medications. Results from this study are expected in the third quarter of 2009.
Initiated DURATION-4 clinical...
Once-Daily Insulin Shot Proves Effective in Study
... insulin three times a day.
The once-a-day formulation, known as insulin glargine
(Lantus), is already on the market, as is insulin lispro (Humalog), which i...good and one is bad."
The new study did show slight benefits for insulin glargine
in terms of patient satisfaction and low blood sugar. But the study was fun...
Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Proposed Dividend
...h type 2 diabetes found that the initiation of insulin
therapy with insulin glargine
(Lantus(R)) was associated with a lower
incidence rate of subsequent myocar...ive analysis which found that initiation of insulin glargine
in patients with type 2 diabetes was associated wit...
glargine in Medical Technology
New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
SAN FRANCISCO, June 8 /PRNewswire-FirstCall/ -- A head-to-head study
announced today at the American Diabetes Association (ADA) meeting
demonstrated that Levemir(R) (insulin detemir [rDNA origin] injection) can
be used once-daily and had a comparable blood glucose response to insulin
Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
ORLANDO, Fla., Nov. 7 /PRNewswire-FirstCall/ -- A retrospective
analysis of healthcare claims in more than 20,000 patients with type 2
diabetes from an integrated U.S. national managed care database found that
the initiation of insulin therapy with insulin glargine
was associated with
a lower ...
Liraglutide provides significantly better glucose control than
insulin glargine in phase 3 study
COPENHAGEN, June 21, 2007-Novo Nordisk today announced clinical
results from the first of five phase 3 studies with liraglutide -
the once-daily human GLP-1 analogue. The 26-week study is part of
the LEAD(TM) (Liraglutide Effect and Action in Diabetes) programme
and included 581 patients with type...
Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
...in combination with a sulfonylurea. Subjects were randomized to receive exenatide once weekly 2 milligrams by subcutaneous injection weekly or insulin glargine
injections administered daily in a variable dose determined by patient blood sugar levels. There was no lead-in or wash-out period. The primary endpoi...
5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH
... the long-term, 5-year study of Lantus(R) (insulin glargine
[rDNA] injection) versus NPH insulin on progressio...ngest randomized controlled study with insulin glargine
versus NPH human insulin ," said lead investig... to 7.8% and 7.6% for all patients in the insuline glargine
and NPH insulin groups respectively). NPH insulin ...
Sanofi-aventis Stands Behind the Safety of Lantus(R)
...e drawn regarding a possible causal relationship between Lantus(R) (insulin glargine
[rDNA] injection) use and the occurrence of malignancies, as the authors of...e gold standard of evidence, do not indicate an association between insulin glargine
"Given the extensive clinical evidence covering over 70,0...
Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients
...% and </=11.0%) despite insulin with/ without oral anti-hyperglycemic therapy were randomized to a 52-week course of either AFRESA (TI) and bedtime glargine
insulin (G) (n=334) or premixed biaspart 70/30 insulin BID (BPA 70/30) twice-a-day (n=343). The primary endpoint was mean change from baseline to week...
New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar
...nsulin Glulisine on Glycemic Control in Type 2 Diabetes Patients on Insulin glargine
and Oral Drugs," evaluating patients adding prandial insulin Apidra(R) (ins... 2 meals or 3 meals daily, already taking basal insulin, Lantus(R) (insulin glargine
[rDNA origin] injection), with or without oral antidiabetic drugs (OADs).Th...
Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
...completed enrollment in the fourth quarter. This approximately
450 patient, open-label, superiority study compares exenatide once weekly with
on a background of oral agent therapy. Results are expected
in the third quarter of 2009.
DURATION-2 completed enrollment in the third quarter...
FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
...twice daily as basal insulin. The majority of
the patients received insulin glargine
as part of their basal-prandial
regimen (69.7% and 72% in the Apidra(R) and...s with type 2 diabetes.
Apidra(R) is from the maker of Lantus(R) (insulin glargine
origin] injection), the number one prescribed insulin.*
glargine in Biological Technology